Occidental Petroleum Corporation vs TG Therapeutics Inc — how do they compare? Occidental Petroleum Corporation trades at $57.8 (market cap $56.20B), while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). The key difference: Occidental Petroleum Corporation is far larger — about 6.8× TG Therapeutics Inc's market cap, and Occidental Petroleum Corporation pays a 1.84% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| OXY | TGTX | |
|---|---|---|
Market Cap | $56.20B | $8.26B |
Sector | Energy | Health |
52-Week High | $66.24 | $59.06 |
52-Week Low | $38.92 | $26.39 |
Enterprise Value | $77.28B | $8.50B |
Dividend Yield | 1.84% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Trailing returns across standard periods
Latest headlines on both assets
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →